Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Shanahan, Kelly [1 ]
Sammons, Sarah [2 ]
Meisel, Jane L. [3 ]
Pluard, Timothy J. [4 ]
Kozlowski, Monica [5 ]
Carroll, Dominic [5 ]
Attias, Elizabeth [5 ]
机构：
[1] Metavivor Res & Support Inc, Annapolis, MD USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Emory Winship Canc Inst, Atlanta, GA USA
[4] St Lukes Canc Inst, Kansas City, MO USA
[5] Sermonix Pharmaceut, Columbus, OH USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-89
引用
下载
收藏
页码：1296 / 1296
页数：1
相关论文
共 50 条
  • [31] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
    Damodaran, Senthil
    Moore, Halle
    O'Sullivan, Ciara C.
    Plourde, Paul V.
    Riordan, Gary
    Sloane, Hillary S.
    Tripathy, Debu
    Carroll, Dominic
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [33] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study
    Goetz, Matthew P.
    Gal-Yam, Einav
    Stover, Daniel
    Sammons, Sarah L.
    Graff, Stephanie L.
    Wang, Grace
    Cristofanilli, Massimo
    Riordan, Gary
    Sloane, Hillary S.
    Carroll, Dominic
    Plourde, Paul V.
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [35] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [36] CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH CARE UTILIZATION IN ER+/HER2-METASTATIC POSTMENOPAUSAL BREAST CANCER PATIENTS: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW IN THE UNITED STATES
    Zanotti, G.
    Hunger, M.
    Perkins, J. J.
    Horblyuk, R.
    Martin, M.
    VALUE IN HEALTH, 2016, 19 (03) : A137 - A138
  • [37] Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2-metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update
    Damodaran, Senthil
    Moore, Halle C. F.
    Anderson, Ian Churchill
    Cherian, Mathew Amprayil
    O'Sullivan, Ciara Catherine
    Plourde, Paul V.
    Portman, David Jay
    Goetz, Matthew P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2-metastatic breast cancer patients
    Manai, Maroua
    Sahraoui, Ghada
    Doghri, Raoudha
    Gerratana, Lorenzo
    D'Amico, Paolo
    Zhang, Youbin
    Donahue, Jeannine
    Shah, Ami
    Reduzzi, Carolina
    Qiang, Wenan
    Cristofanilli, Massimo
    CANCER RESEARCH, 2024, 84 (09)
  • [39] The mutational profile of ER-, PR+, HER2-metastatic breast cancer.
    Fischbach, Neal A.
    Huang, Richard S. P.
    Lustberg, Maryam B.
    Pelletier, Maureen
    Pusztai, Lajos
    Sivakumar, Smruthy
    Sokol, Ethan
    Ross, Jeffrey S.
    Levy, Mia Alyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
12345